FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097875948> ?p ?o ?g. }

• W3097875948 abstract "Abstract Background This study reports the global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program between 2012 and 2016. Methods For the 2012–2016 ATLAS program, 205 medical centers located in Africa-Middle East (n = 12), Asia–Pacific (n = 32), Europe (n = 94), Latin America (n = 26), North America (n = 31), and Oceania (n = 10) consecutively collected the clinical isolates. The minimum inhibitory concentrations (MICs) and in vitro susceptibilities to ceftaroline and ceftazidime–avibactam were assessed using the Clinical and Laboratory Standards Institute (CLSI) 2019and European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2019 guidelines. Results Between 2012 and 2016, 176,345 isolates were collected from around the globe and included in the analysis. Regarding Gram-negative bacteria, ceftazidime–avibactam demonstrated high susceptibility (> 90%) against Enterobacteriaceae and Pseudomonas aeruginosa , with increased antimicrobial activity observed from the addition of avibactam (4 mg/L) to ceftazidime. Regarding Gram-positive bacteria, ceftaroline showed > 90% susceptibility against Staphylococcus aureus , Streptococcus pneumoniae , α-and β-hemolytic Streptococcus . The antimicrobial susceptibilities to ceftaroline and ceftazidime–avibactam were mostly stable from 2012 to 2016, but the susceptibilities to ceftazidime–avibactam to carbapenem-resistant (CR) Klebsiella pneumonia (88.4–81.6%) and to CR- P. aeruginosa (89.6–72.7%) decreased over time. In terms of regional difference, the susceptibilities of methicillin-resistant S. aureus to ceftaroline in Asia and of CR- K. pneumonia to ceftazidime–avibactam in Asia/Africa-Middle East were lower compared with other regions, while the susceptibility of CR- P. aeruginosa to ceftazidime–avibactam in North America was higher. Conclusion The addition of avibactam improves the activity of ceftazidime against Enterobacteriaceae and P. aeruginosa . The global antimicrobial susceptibilities to ceftaroline and ceftazidime–avibactam were, in general, stable from 2012 to 2016, but a marked reduction in the susceptibilities of specific species and CR- P. aeruginosa to ceftazidime–avibactam was observed." @default.
• W3097875948 created "2020-11-09" @default.
• W3097875948 creator A5005303316 @default.
• W3097875948 creator A5015563284 @default.
• W3097875948 creator A5016330183 @default.
• W3097875948 creator A5024421296 @default.
• W3097875948 creator A5026565474 @default.
• W3097875948 creator A5036929507 @default.
• W3097875948 creator A5038605675 @default.
• W3097875948 creator A5045017388 @default.
• W3097875948 creator A5053457596 @default.
• W3097875948 creator A5076016269 @default.
• W3097875948 creator A5078581178 @default.
• W3097875948 creator A5083455588 @default.
• W3097875948 creator A5086015188 @default.
• W3097875948 date "2020-10-27" @default.
• W3097875948 modified "2023-10-15" @default.
• W3097875948 title "Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)" @default.
• W3097875948 cites W1544047118 @default.
• W3097875948 cites W1616860288 @default.
• W3097875948 cites W1975720108 @default.
• W3097875948 cites W1998268643 @default.
• W3097875948 cites W2030747641 @default.
• W3097875948 cites W2063994252 @default.
• W3097875948 cites W2068735589 @default.
• W3097875948 cites W2098179352 @default.
• W3097875948 cites W2140353364 @default.
• W3097875948 cites W2154556219 @default.
• W3097875948 cites W2274251352 @default.
• W3097875948 cites W2312102558 @default.
• W3097875948 cites W2314729869 @default.
• W3097875948 cites W2325192560 @default.
• W3097875948 cites W2469482960 @default.
• W3097875948 cites W2547030791 @default.
• W3097875948 cites W2569030127 @default.
• W3097875948 cites W2753460377 @default.
• W3097875948 cites W2779019546 @default.
• W3097875948 cites W2787688691 @default.
• W3097875948 cites W2801851274 @default.
• W3097875948 cites W2809480590 @default.
• W3097875948 cites W2822687727 @default.
• W3097875948 cites W2897561836 @default.
• W3097875948 cites W2904057341 @default.
• W3097875948 cites W2904468608 @default.
• W3097875948 cites W2921342657 @default.
• W3097875948 cites W2921352118 @default.
• W3097875948 cites W2947132738 @default.
• W3097875948 cites W4241111610 @default.
• W3097875948 cites W4250547697 @default.
• W3097875948 doi "https://doi.org/10.1186/s13756-020-00829-z" @default.
• W3097875948 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7590473" @default.
• W3097875948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33109242" @default.
• W3097875948 hasPublicationYear "2020" @default.
• W3097875948 type Work @default.
• W3097875948 sameAs 3097875948 @default.
• W3097875948 citedByCount "16" @default.
• W3097875948 countsByYear W30978759482020 @default.
• W3097875948 countsByYear W30978759482021 @default.
• W3097875948 countsByYear W30978759482022 @default.
• W3097875948 countsByYear W30978759482023 @default.
• W3097875948 crossrefType "journal-article" @default.
• W3097875948 hasAuthorship W3097875948A5005303316 @default.
• W3097875948 hasAuthorship W3097875948A5015563284 @default.
• W3097875948 hasAuthorship W3097875948A5016330183 @default.
• W3097875948 hasAuthorship W3097875948A5024421296 @default.
• W3097875948 hasAuthorship W3097875948A5026565474 @default.
• W3097875948 hasAuthorship W3097875948A5036929507 @default.
• W3097875948 hasAuthorship W3097875948A5038605675 @default.
• W3097875948 hasAuthorship W3097875948A5045017388 @default.
• W3097875948 hasAuthorship W3097875948A5053457596 @default.
• W3097875948 hasAuthorship W3097875948A5076016269 @default.
• W3097875948 hasAuthorship W3097875948A5078581178 @default.
• W3097875948 hasAuthorship W3097875948A5083455588 @default.
• W3097875948 hasAuthorship W3097875948A5086015188 @default.
• W3097875948 hasBestOaLocation W30978759481 @default.
• W3097875948 hasConcept C176947019 @default.
• W3097875948 hasConcept C2775933652 @default.
• W3097875948 hasConcept C2776933286 @default.
• W3097875948 hasConcept C2776968632 @default.
• W3097875948 hasConcept C2777406300 @default.
• W3097875948 hasConcept C2777637488 @default.
• W3097875948 hasConcept C2779489039 @default.
• W3097875948 hasConcept C2780950330 @default.
• W3097875948 hasConcept C2781253189 @default.
• W3097875948 hasConcept C4937899 @default.
• W3097875948 hasConcept C501593827 @default.
• W3097875948 hasConcept C523546767 @default.
• W3097875948 hasConcept C54355233 @default.
• W3097875948 hasConcept C71924100 @default.
• W3097875948 hasConcept C86803240 @default.
• W3097875948 hasConcept C89423630 @default.
• W3097875948 hasConceptScore W3097875948C176947019 @default.
• W3097875948 hasConceptScore W3097875948C2775933652 @default.
• W3097875948 hasConceptScore W3097875948C2776933286 @default.
• W3097875948 hasConceptScore W3097875948C2776968632 @default.
• W3097875948 hasConceptScore W3097875948C2777406300 @default.
• W3097875948 hasConceptScore W3097875948C2777637488 @default.
• W3097875948 hasConceptScore W3097875948C2779489039 @default.
• W3097875948 hasConceptScore W3097875948C2780950330 @default.
• W3097875948 hasConceptScore W3097875948C2781253189 @default.

• next